Your browser is no longer supported. Please, upgrade your browser.
Settings
GKOS Glaukos Corporation daily Stock Chart
GKOS [NYSE]
Glaukos Corporation
Index- P/E- EPS (ttm)-0.37 Insider Own0.90% Shs Outstand35.98M Perf Week-2.71%
Market Cap2.55B Forward P/E1183.50 EPS next Y0.06 Insider Trans-30.72% Shs Float34.70M Perf Month-11.32%
Income-13.00M PEG- EPS next Q-0.11 Inst Own- Short Float9.71% Perf Quarter16.62%
Sales181.30M P/S14.09 EPS this Y16.20% Inst Trans-3.77% Short Ratio8.78 Perf Half Y18.35%
Book/sh4.82 P/B14.73 EPS next Y119.40% ROA-7.10% Target Price73.25 Perf Year134.28%
Cash/sh3.90 P/C18.18 EPS next 5Y32.60% ROE-8.20% 52W Range30.28 - 83.14 Perf YTD26.42%
Dividend- P/FCF297.09 EPS past 5Y2.90% ROI-7.80% 52W High-13.95% Beta1.58
Dividend %- Quick Ratio5.40 Sales past 5Y54.00% Gross Margin86.20% 52W Low136.26% ATR2.85
Employees437 Current Ratio5.80 Sales Q/Q29.70% Oper. Margin-7.20% RSI (14)44.98 Volatility4.51% 3.81%
OptionableYes Debt/Eq0.00 EPS Q/Q69.70% Profit Margin-7.10% Rel Volume0.83 Prev Close71.01
ShortableYes LT Debt/Eq0.00 EarningsMay 08 AMC Payout- Avg Volume383.67K Price71.54
Recom2.00 SMA20-4.79% SMA50-1.61% SMA20018.67% Volume68,628 Change0.75%
Mar-08-19Initiated BTIG Research Neutral
Aug-30-18Initiated Berenberg Hold $57
Aug-29-18Upgrade JP Morgan Neutral → Overweight
Aug-03-18Reiterated Stifel Hold $32 → $35
Jun-21-18Downgrade JP Morgan Overweight → Neutral
Apr-13-18Downgrade Stifel Buy → Hold $39 → $32
Mar-01-18Reiterated Cantor Fitzgerald Buy $48 → $43
Mar-02-17Reiterated Cantor Fitzgerald Overweight $45 → $54
Jan-06-17Upgrade Stifel Hold → Buy $42 → $45
Oct-27-16Initiated Wells Fargo Outperform
Aug-02-16Reiterated Cantor Fitzgerald Buy $35 → $41
Jun-03-16Initiated Cantor Fitzgerald Buy $35
Apr-08-16Initiated Stifel Hold
Feb-09-16Initiated Piper Jaffray Overweight $19
Jul-20-15Initiated JP Morgan Overweight $38
Jul-20-15Initiated Goldman Neutral $29
Jul-20-15Initiated Cantor Fitzgerald Buy $35
Jul-20-15Initiated BofA/Merrill Buy
Apr-17-19 04:15PM  Glaukos Corporation to Release First Quarter 2019 Financial Results after Market Close on May 8 Business Wire -5.33%
Apr-15-19 07:00AM  Prospective, Randomized Trial Highlights 5-Year Performance of 2 Standalone Glaukos iStents® vs. Topical Prostaglandin in Newly Diagnosed Glaucoma Patients Business Wire
Apr-12-19 01:31PM  Is Glaukos Corporation (NYSE:GKOS) A Volatile Stock? Simply Wall St.
Apr-02-19 10:20AM  Glaukos (GKOS) Banks on Solid Pipeline Amid Stiff Competition Zacks
Apr-01-19 07:15AM  New Research: Key Drivers of Growth for Fresh Del Monte Produce, Baker Hughes, a GE company, HollyFrontier, Glaukos, HCI Group, and Revance Therapeutics Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Mar-15-19 07:00AM  Pivotal Trial Results for Glaukos iStent inject® Published in Leading Ophthalmic Journal Business Wire
Mar-13-19 04:15PM  Glaukos Technologies Featured in Numerous Presentations at 2019 American Glaucoma Society Meeting Business Wire
01:06PM  When Should You Buy Glaukos Corporation (NYSE:GKOS)? Simply Wall St.
Mar-12-19 04:15PM  International Glaucoma Study Confirms Long-term Efficacy and Safety Profile of Glaukos iStent® Implantation in Combination with Cataract Surgery Business Wire
Mar-07-19 08:16AM  Why Glaukos Stock Jumped 16.3% in February Motley Fool
Mar-04-19 12:07AM  Edited Transcript of GKOS earnings conference call or presentation 27-Feb-19 9:30pm GMT Thomson Reuters StreetEvents -6.07%
Feb-27-19 11:16PM  Glaukos Corp (GKOS) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:10PM  Glaukos Corporation Announces Fourth Quarter and Full Year 2018 Financial Results Business Wire
Feb-20-19 10:31AM  Earnings Preview: Glaukos (GKOS) Q4 Earnings Expected to Decline Zacks
Feb-06-19 04:15PM  Glaukos Corporation to Release Fourth Quarter and Full Year 2018 Financial Results after Market Close on February 27 Business Wire
Jan-17-19 07:17AM  Have Insiders Been Selling Glaukos Corporation (NYSE:GKOS) Shares This Year? Simply Wall St.
Jan-11-19 12:24PM  Tamarack Capital Managements Return, AUM, and Holdings Insider Monkey
Dec-22-18 04:17AM  Hedge Funds Are Betting On Glaukos Corporation (GKOS) Insider Monkey
Dec-19-18 04:15PM  Glaukos Announces Participation in J.P. Morgan Healthcare Conference Business Wire
Dec-11-18 04:15PM  Glaukos iStent inject® Implantation with Concomitant Cataract Surgery Provides Sustained Reduction in IOP and Medication Burden, According to New Study Business Wire
Nov-27-18 07:45AM  Consolidated Research: 2018 Summary Expectations for The Hackett Group, Green Plains, Malibu Boats, Hawaiian Electric Industries, Iridium Communications, and Glaukos Fundamental Analysis, Key Performance Indications GlobeNewswire
Nov-22-18 09:09AM  Is Glaukos Corporations (NYSE:GKOS) CEO Pay Fair? Simply Wall St.
Nov-14-18 04:15PM  Glaukos Announces Participation in Piper Jaffray Healthcare Conference Business Wire
01:36AM  Edited Transcript of GKOS earnings conference call or presentation 7-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Nov-07-18 07:55PM  Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates Zacks +5.21%
06:52PM  Glaukos: 3Q Earnings Snapshot Associated Press
04:10PM  Glaukos Corporation Announces Third Quarter 2018 Financial Results Business Wire
Oct-26-18 07:00AM  Glaukos Technologies Featured in Presentations at 2018 American Academy of Ophthalmology Conference Business Wire
Oct-23-18 08:00AM  Today's Research Reports on Trending Tickers: Inogen and Glaukos ACCESSWIRE
Oct-17-18 07:00AM  Glaukos Corporation to Release Third Quarter 2018 Financial Results after Market Close on November 7 Business Wire
Oct-15-18 08:10AM  Detailed Research: Economic Perspectives on DDR, Acuity Brands, Douglas Emmett, Glaukos, US Ecology, and Lear What Drives Growth in Today's Competitive Landscape GlobeNewswire
Sep-21-18 07:00AM  Multiple Surgeon Presentations to Showcase Glaukos Products at 2018 European Society of Cataract and Refractive Surgeons Congress Business Wire
Sep-04-18 09:45AM  An Apple A Day Can't Keep Strong Gains Away From These 5 Hot Medical Stocks Investor's Business Daily
Aug-30-18 08:00AM  Today's Research Reports on Trending Tickers: Glaukos and STAAR Surgical ACCESSWIRE +7.22%
Aug-29-18 04:30PM  Why Square, Glaukos, and Ballard Power Systems Jumped Today Motley Fool +40.31%
02:06PM  JPMorgan Upgrades Glaukos On CyPass News, Likely Market Share Boost Benzinga
12:32PM  Why Glaukos Corporation Stock Is Soaring Today Motley Fool
Aug-22-18 04:15PM  Glaukos Announces Participation in Wells Fargo Healthcare Conference Business Wire
Aug-14-18 07:54PM  Edited Transcript of GKOS earnings conference call or presentation 2-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
07:40AM  Investor Expectations to Drive Momentum within American Vanguard, Glaukos, United Natural Foods, Walker & Dunlop, Unisys, and Comfort Systems Discovering Underlying Factors of Influence GlobeNewswire
Aug-03-18 09:25AM  Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates Zacks -12.49%
05:09AM  Glaukos: 2Q Earnings Snapshot Associated Press
Aug-02-18 04:15PM  Glaukos Corporation Announces Second Quarter 2018 Financial Results Business Wire
04:15PM  Glaukos Announces Pharmaceutical Development Agreement with D. Western Therapeutics Institute, Inc. Business Wire
02:30PM  Glaukos Corp to Host Earnings Call ACCESSWIRE
Jul-31-18 07:31AM  Free Pre-Market Technical Recap on DENTSPLY SIRONA and Three Additional Medical Supplies Stocks ACCESSWIRE +5.21%
Jul-19-18 07:00AM  Glaukos Corporation to Release Second Quarter 2018 Financial Results after Market Close on August 2 Business Wire
Jun-29-18 07:20AM  Free Technical Research on Valeritas Holdings and Three More Medical Supplies Equities ACCESSWIRE
Jun-25-18 07:00AM  Glaukos Announces FDA Approval for the iStent inject® Trabecular Micro-Bypass System Business Wire
May-30-18 04:15PM  Glaukos Announces Participation in William Blair Growth Stock Conference Business Wire
May-29-18 07:00AM  Free Daily Technical Summary Reports on Endologix and Three Other Medical Supplies Stocks ACCESSWIRE
May-24-18 03:00AM  Glaukos Gets RS Rating Upgrade Investor's Business Daily
May-22-18 08:35PM  Is There Now An Opportunity In Glaukos Corporation (NYSE:GKOS)? Simply Wall St.
May-16-18 08:20AM  New Research Coverage Highlights Ellie Mae, Micron Technology, Applied Optoelectronics, Acadia Realty Trust, Glaukos, and Noble Energy Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
May-12-18 05:47PM  Edited Transcript of GKOS earnings conference call or presentation 9-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-09-18 06:16PM  Glaukos: 1Q Earnings Snapshot Associated Press
04:15PM  Glaukos Corporation Announces First Quarter 2018 Financial Results Business Wire
May-02-18 07:00AM  Glaukos Announces Participation in Bank of America Merrill Lynch 2018 Health Care Conference Business Wire
Apr-23-18 08:19AM  Is SPDR S&P Health Care Equipment ETF (XHE) a Hot ETF Right Now? Zacks
Apr-19-18 04:30PM  Glaukos Corporation to Release First Quarter 2018 Financial Results after Market Close on May 9 Business Wire
Apr-14-18 03:30PM  IDE Pivotal Trial Results for Glaukos iStent inject® Show Significant Reductions in Unmedicated IOP in Glaucoma Subjects Undergoing Cataract Surgery Business Wire
08:00AM  Glaukos Files Patent Infringement Lawsuit Against Ivantis, Inc. Business Wire
Apr-13-18 12:45PM  Why Glaukos Corp. Is Sinking Today Motley Fool -9.94%
09:27AM  Stifel's Doctor Survey Triggers Glaukos Downgrade Benzinga
Apr-11-18 07:00AM  Multiple Surgeon Presentations to Include Glaukos Technologies at 2018 American Society of Cataract and Refractive Surgery Business Wire
Mar-26-18 09:16AM  Edited Transcript of GKOS earnings conference call or presentation 28-Feb-18 9:30pm GMT Thomson Reuters StreetEvents
Mar-02-18 07:00AM  Glaukos Announces Participation in 30th Annual ROTH Conference Business Wire
Feb-28-18 05:57PM  Glaukos tops Street 4Q forecasts Associated Press
04:10PM  Glaukos Corporation Announces Fourth Quarter and Full Year 2017 Financial Results Business Wire
12:00PM  Glaukos Corp to Host Earnings Call ACCESSWIRE
09:35AM  Glaukos Q4 Earnings Outlook Benzinga
Feb-27-18 04:30PM  Glaukos Technologies Featured in Numerous Presentations at 2018 American Glaucoma Society Meeting Business Wire
07:00AM  International Study Shows Long-Term Titrated IOP Control with 1, 2 or 3 Glaukos iStent® Trabecular Micro-Bypass Stents in Open-Angle Glaucoma Patients Business Wire
Feb-13-18 08:10AM  Detailed Research: Economic Perspectives on Omega Healthcare Investors, Vanda Pharmaceuticals, Acushnet, Prospect Capital, Intercontinental Exchange, and Glaukos What Drives Growth in Today's Competitive Landscape GlobeNewswire
Feb-08-18 07:00AM  Glaukos iStent® Trabecular Micro-Bypass Stent Reduced IOP and Lowered Medication Burden in Patients with Severe Glaucoma, According to New Study Business Wire
Feb-07-18 07:00AM  Glaukos Corporation to Release Fourth Quarter and Full Year 2017 Financial Results after Market Close on February 28 Business Wire
Jan-10-18 08:06AM  See what the IHS Markit Score report has to say about Glaukos Corp. Markit
07:00AM  Glaukos Corporations iDose Travoprost Achieves Sustained IOP Reduction and Favorable Safety Profile in 12-Month Interim Cohort Business Wire
Jan-09-18 08:05AM  See what the IHS Markit Score report has to say about Glaukos Corp. Markit
Jan-03-18 07:00AM  Glaukos Submits IDE Application to FDA to Study iStent infinite Trabecular Micro-Bypass System Business Wire
Dec-29-17 07:50AM  Wired News - Glaukos Submits Pre-Market Approval Application to FDA For iStent Inject(R) Trabecular Micro-Bypass ACCESSWIRE
Dec-27-17 04:30PM  Glaukos Announces Participation in J.P. Morgan Healthcare Conference Business Wire
01:48PM  Glaukos Has 84% Upside Potential In 2018, According To Cantor Benzinga
07:00AM  Glaukos Announces Submission of Pre-Market Approval Application for the iStent Inject® Trabecular Micro-Bypass Business Wire
Dec-26-17 11:34AM  ETFs with exposure to Glaukos Corp. : December 26, 2017 Capital Cube
Dec-22-17 09:20AM  Glaukos Corp. :GKOS-US: Earnings Analysis: Q3, 2017 By the Numbers : December 22, 2017 Capital Cube
08:03AM  See what the IHS Markit Score report has to say about Glaukos Corp. Markit
Dec-21-17 08:03AM  See what the IHS Markit Score report has to say about Glaukos Corp. Markit
Dec-19-17 07:00AM  Glaukos to Begin Randomized U.S. IDE Pivotal Clinical Trial for the iStent SA System Business Wire
Dec-11-17 04:30PM  Why SCANA, Glaukos, and Juno Therapeutics Slumped Today Motley Fool
08:03AM  See what the IHS Markit Score report has to say about Glaukos Corp. Markit
Dec-01-17 08:05AM  See what the IHS Markit Score report has to say about Glaukos Corp. Markit
Nov-30-17 08:05AM  See what the IHS Markit Score report has to say about Glaukos Corp. Markit
07:00AM  Glaukos Announces Issuance of New U.S. Patent Business Wire
Nov-29-17 08:06AM  See what the IHS Markit Score report has to say about Glaukos Corp. Markit
Nov-27-17 08:05AM  See what the IHS Markit Score report has to say about Glaukos Corp. Markit
07:30AM  Research Report Identifies Walker & Dunlop, Vanda Pharmaceuticals, Acushnet, SS&C Technologies, ManpowerGroup, and Glaukos with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Nov-22-17 08:07AM  See what the IHS Markit Score report has to say about Glaukos Corp. Markit
Nov-17-17 08:06AM  See what the IHS Markit Score report has to say about Glaukos Corp. Markit
Nov-16-17 11:38AM  ETFs with exposure to Glaukos Corp. : November 16, 2017 Capital Cube
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma; and iStent inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry for the reduction of intraocular pressure in mild-to-moderate open-angle glaucoma in combination with cataract surgery. The company's product pipeline includes iStent Infinite trabecular micro-bypass system, which is used as a standalone procedure in patients with refractory glaucoma; iStent Supra suprachoroidal micro-bypass stent that is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye; iStent SA trabecular micro-bypass system, a two-stent product, which uses a different auto-injection inserter designed for use in a standalone procedure; and iDose, a targeted injectable drug delivery implant that is designed to be pre-loaded into a small gauge needle and injected into the eye through a self-sealing corneal needle penetration. The company markets its products through direct sales force in the United States and other 16 countries, as well as through distribution partners in Europe, the Asia Pacific, Latin America, and internationally. Glaukos Corporation was founded in 1998 and is headquartered in San Clemente, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Calcaterra Chris M.Chief Operating OfficerMar 06Sale66.2916,6041,100,754150,000Mar 07 06:17 PM
Calcaterra Chris M.Chief Operating OfficerMar 05Sale68.0173,3964,991,411166,604Mar 07 06:17 PM
Gilliam Joseph ECFO, SVP Corporate DevelopmentFeb 19Sale70.035,000350,15075,694Feb 21 04:19 PM
Gilliam Joseph ECFO, SVP Corporate DevelopmentNov 28Sale60.035,000300,15086,117Nov 29 05:33 PM
Gilliam Joseph ECFO, SVP Corporate DevelopmentNov 26Sale58.372,100122,57791,117Nov 27 06:08 PM
LINK WILLIAM J PHDDirectorNov 15Sale57.4127,0251,551,47740,479Nov 15 06:28 PM
LINK WILLIAM J PHDDirectorNov 13Sale58.0114,475839,69576,004Nov 15 06:28 PM
Kliman Gilbert HDirectorAug 30Sale62.392,760172,1964,633Aug 31 12:31 PM
Kliman Gilbert HDirectorAug 29Sale60.38500,00030,187,750518,362Aug 31 12:31 PM
Burns Thomas WilliamChief Executive OfficerAug 07Option Exercise2.0151,115102,892328,355Aug 08 07:13 PM
Burns Thomas WilliamChief Executive OfficerAug 07Sale39.5051,1152,019,062277,240Aug 08 07:13 PM
Burns Thomas WilliamChief Executive OfficerAug 06Option Exercise1.9398,885190,354376,125Aug 08 07:13 PM
Burns Thomas WilliamChief Executive OfficerAug 06Sale38.4198,8853,798,087277,240Aug 08 07:13 PM
Calcaterra Chris M.Chief Operating OfficerAug 02Option Exercise16.4938,983642,830278,983Aug 03 07:35 PM
Calcaterra Chris M.Chief Operating OfficerAug 02Sale44.4438,9831,732,464240,000Aug 03 07:35 PM
Calcaterra Chris M.Chief Operating OfficerJun 20Option Exercise7.202,47017,795242,470Jun 21 04:07 PM
Calcaterra Chris M.Chief Operating OfficerJun 20Sale44.032,470108,754240,000Jun 21 04:07 PM
Calcaterra Chris M.Chief Operating OfficerJun 19Option Exercise4.237,75932,782247,759Jun 21 04:07 PM
Calcaterra Chris M.Chief Operating OfficerJun 19Sale44.017,759341,474240,000Jun 21 04:07 PM
Calcaterra Chris M.Chief Operating OfficerJun 15Option Exercise4.238,77137,057248,771Jun 15 05:53 PM
Calcaterra Chris M.Chief Operating OfficerJun 15Sale44.018,771386,012240,000Jun 15 05:53 PM